Baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, HER2-positive early stage breast cancer when comparing de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy, vs trastuzumab plus endocrine therapy.
Read More
18F-DCFPyL Could Become a Key Diagnostic Tool for Biochemical Recurrence in Prostate Cancer
September 13th 202118F-DCFPyL, a PET prostate specific membrane antigen targeting agent, demonstrated statistically significant potential in detecting biochemical recurrence in men with prostate cancer.
Read More
Lenvatinib Treatment Can Continue in Unresectable HCC With Child–Pugh Class-B Liver Function
July 1st 2021Lenvatinib can continue to be administered in patients with unresectable hepatocellular carcinoma that has Child-Pugh class B liver function, as they experienced a similar tumor size reduction as their Child-Pugh class A counterparts in a post-hoc analysis of the phase 3 REFLECT trial.
Read More
Daratumumab Plus Standard of Care Continues to Improve Survival in Newly Diagnosed Multiple Myeloma
June 12th 2021The addition of daratumumab to lenalidomide and dexamethasone continued to reduced the risk of death by 32% compared with Rd alone in patients with newly diagnosed multiple myeloma who are transplant ineligible after almost 5 years of follow-up.
Read More
Lenalidomide/Rituximab Continues to Improve PFS in iNHL, MCL
June 11th 2021The combination of lenalidomide and rituximab continued to improve progression-free survival with durable outcomes and a manageable safety profile in patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.
Read More
Fracture Risk Reduced With BPAs During Radium-223/Enzalutamide Treatment in mCRPC
June 8th 2021Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.
Read More
Adjuvant Chemotherapy Fails to Improve PFS and OS in Locally Advanced Cervical Cancer
June 3rd 2021The administration of adjuvant carboplatin and paclitaxel following standard cisplatin-based chemoradiation failed to demonstrate an improvement in progression-free survival or overall survival in women with locally advanced cervical cancer, according to findings from the phase 3 OUTBACK trial.
Read More
PSMA-Targeted Agent Shows Potential Utility in Identifying Relapsed Prostate Cancer
February 12th 2021February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.
Read More
Stem Cell Recipients Develop Robust Immunity Against SARS-CoV2 and Common Human Coronaviruses
February 8th 2021February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.
Read More
Pembrolizumab Continues to Improve Survival in PD-L1–Positive Advanced NSCLC
January 28th 2021January 28, 2021 - Pembrolizumab continued to demonstrate a clinically meaningful improvement in overall and progression-free survival, compared with docetaxel, in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer after more than 5 years of follow-up.
Read More
Frontline Pembrolizumab Improves PFS2, HRQoL in MSI-H/dMMR mCRC
January 16th 2021January 16, 2021 - Frontline use of pembrolizumab monotherapy significantly improved progression-free survival, while demonstrating superior safety, compared with chemotherapy in patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer.
Read More
Women Who Undergo Mastectomy with Reconstruction At Higher Risk for Chronic Controlled Substance Use
December 9th 2020December 9, 2020 - Among women who underwent a mastectomy plus reconstructive surgery, those who received a breast cancer diagnosis, received chemotherapy and were younger were reported to have a higher risk of new chronic controlled substance use.
Read More
Subcutaneous Daratumumab Combo Improves PFS in Relapsed/Refractory Multiple Myeloma
December 7th 2020December 7, 2020 - The addition of subcutaneous daratumumab to pomalidomide and dexamethasone significantly reduced the risk of progression or death by 37%, compared with pomalidomide and dexamethasone, in patients with relapsed/refractory multiple myeloma who had received ≥1 prior line of therapy.
Read More
Updated Findings Show Olaparib Prolongs OS in Men with mCRPC
September 20th 2020Olaparib induced a significantly longer duration of overall survival, compared with enzalutamide or abiraterone plus prednisone, in men with metastatic castration-resistant prostate cancer who had tumors with at least 1 alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent.
Read More
Frontline Nivolumab/Ipilimumab Combo with Limited Chemo Improves OS in NSCLC
May 30th 2020Results from the CheckMate 9LA suggested that frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer should be considered a new option for this population.
Read More
Nivolumab/Ipilimumab Combo Induces Durable Responses in Advanced NSCLC
May 29th 2020Following at least 3 years of follow-up, patients with advanced non-small cell lung cancer and tumor PD-L1 expression ≥ 1% or < 1% experienced durable and long-term efficacy benefits from frontline treatment with nivolumab plus ipilimumab, compared with chemotherapy.
Read More